Uveitis Treatment Market Share Analysis of The Top Industry Players, Growth Opportunities and Country Level Segments

Globally, North America is the largest, while Asia-Pacific is the fastest growing uveitis treatment market. The uveitis treatment market is witnessing significant growth, due to increasing prevalence of uveitis and related complications. The global uveitis treatment market currently has many technologically innovative products in the pipeline, which are expected to improve efficiency and safety profiles in the clinical trial stage of development, thereby reducing the progression of disease considerably. 

 

Anterior uveitis represents the largest growing segment of global uveitis treatment market, as per the type of uveitis. Anterior uveitis refers to redness in the middle layer of an eye, which contains ciliary body and iris. Anterior uveitis might be chronic or acute in nature. Anterior uveitis is caused primarily due to fungal, bacterial or viral infections and auto-immune disorders. The treatment for uveitis is primarily based on steroids and immunosuppressants. The global uveitis treatment market is currently dominated by uveitis treatment through corticosteroid (steroid medication) as well as off-label immuno-suppressive and biologic drugs.

Request to Get the Sample Pages at:

The global uveitis treatment market is witnessing substantial growth due to increased aging population, growing prevalence of uveitis and related complications. Moreover, introduction of innovative biologics, fast-track approval of pipeline drugs, increasing research and development investments in drug discovery and development, rising government initiatives to minimize eye disorders are also driving the growth of the global uveitis treatment market. Introduction of new routes for drug administration that improves the efficiency of the drug is another significant driver for uveitis treatment market. With the advancement of molecular biology, some intravitreal implants and biologic agents are increasingly used for the treatment of uveitis. By the development of molecular biology, more therapeutic agents and approaches have been applied to control ocular inflammation caused by uveitis, which are expected to have a positive influence on the uveitis treatment market. The advancements anticipated from the uveitis treatment options currently in the pipeline are sparking out serious market growth.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=uveitis-treatment-market

However, the adverse effects related to uveitis treatment medication such as watery eyes, irritation and others are the factors which are expected to hinder growth of the global uveitis treatment market. Poor primary healthcare infrastructure, lack of awareness about eye disorders, and lack of health insurance in developing countries are also obstructing the uveitis treatment market.

Some of the major competitors in the global uveitis treatment market are XOMA, pSivida Corp., Novartis, Allergan India Private Limited, Enzo Biochem Inc., AbbVie Inc., Bausch & Lomb Incorporated, Ophthalix Inc., Santen Pharmaceutical Co., Ltd., Topivert Ltd, HANALL and Regeneron Pharmaceuticals, Inc.

Read More

Protein A Resin Market to Witness the Highest Growth Globally in Coming Years

The global protein A resin market is expected to witness considerable growth during the forecast period due to the increasing research and development activities and increasing prevalence of chronic diseases. High traction for monoclonal antibodies in biopharmaceutical industry is supporting the growth of the global market. The increasing demand for monoclonal antibodies has fueled the need for high capacity commercial scale purification of monoclonal antibodies.

Protein A resins are designed for the simple and rapid purification of antibodies. Therefore, an increase in demand for monoclonal antibodies implies an increase in demand for protein A resins. The market for natural protein A resin was the larger than recombinant protein A resin market in 2015; however, recombinant protein A resin market is expected to witness the higher growth during the forecast period.

Request to Get the Sample Pages at:

Protein A, a 56 kDa surface protein, is found on the cell wall of Staphylococcus aureus bacterium. The protein has immunoglobulin-binding domains which bind to proteins, mostly immunoglobulin G (IgG). Protein A binds to the Fc region or Fab region of immunoglobulins, thus, increasingly being used for immune precipitation or antibody purification applications. Protein A ligand is used for the affinity chromatography step in commercial-scale production of monoclonal antibodies. The key factors driving the use of protein A resin for antibody purification are high antibody selectivity, increased antibody yield and excellent antibody purity, and ease of operation in large as well as small scale antibody purification.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=protein-a-resin-market

Geographically, North America accounted for the largest share in the global protein A resin market in 2015, owing to the large number of clinical trials for the monoclonal antibody based therapeutics and increasing traction for biosimilars with the recent U.S. Food and Drugs Administration in the region. The U.S. contributed largest revenue to the North American as well as global protein A resin market. The country is expected to remain the largest market for protein A resin globally during the forecast period.

The protein A resin market is expected to witness the highest growth in Asia-Pacific during the forecast period. The highest growth in the region is attributed to the increasing compliance for biosimilars and shifting global interest for expanding biopharmaceutical manufacturing capacities in the emerging economies of the region.

The key players operating in the global protein A resin market are General Electric Company, Thermo Fisher Scientific Inc., Merck KGaA, Tosoh Corporation, Repligen Corporation, Novasep, Expedeon Ltd., and GenScript.

Read More

Pompe Disease Market - Epidemiology Analysis, Therapy, Growth and Demand Forecast to 2024

The pompe disease market is growing at a significant rate mainly due to special provisions for orphan drugs. Regulatory assistance in emerging nations is one of the major trends seen in the pompe disease market.

Pompe disease is a type of lysergic acid diethylamide (LSD). LSD refers to a group of diseases arising from the increase of specific substrates and is inherited autosomal recessive disorders. Lysergic acid diethylamide is progressive and having uneven age of onset and clinical symptoms. Pompe disease is a hereditary and repeatedly incurable disorder caused by lack of acid alpha glucosidase, an enzyme desired to split down glycogen in particular structures of our body.

Patients having pompe disease have little amount of or no acid alpha glucosidase enzyme activity, so break down of glycogen is not possible. The additional glycogen builds up in the patient and is stored in skeletal muscle, heart and other tissues, which causes the progressive indications of pompe disease. Increase of glycogen in certain organs and tissues restraints normal functions of patient’s organs. Pompe disease is also known by other names such as glycogen storage disease type II, acid maltase deficiency, lysosomal alpha-glucosidase deficiency, acid alpha-glucosidase deficiency and glycogenosis type II.

Request to Get the Sample Pages at:

Pompe disease is categorized into two broad categories as adult-onset pompe disease and infantile onset pompe disease. Both the parents pass on one strangely altered copy of the gene to their child. A parent with an altered copy of the gene is known as a carrier and the disease can affect both men and women irrespective of the gender. The disease is acquired by the individuals at the time of birth only, but the onset of indications differs significantly. The researchers have identified more than 300 genetic mutations that can cause pompe disease. Enzyme replacement therapy and diet therapy are useful in dropping the clinical demonstrations of the disease.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=pompe-disease-market

Government regulations, such as orphan drug exclusivity and limited patient population are the factors restraining the growth of the pompe disease market.

Some of the competitors in the market are Genzyme Corporation, EpiVax, Inc., Amicus Therapeutics, Audentes Therapeutics, BioMarin Pharmaceutical Inc., Valerion Therapeutics, LLC, Oxyrane, and Sangamo BioSciences Inc.

Read More

Pancreatic Cancer Therapeutics Market - Epidemiology Analysis, Therapy, Development, Growth and Demand Forecast to 2024

The global pancreatic cancer therapeutics market holds numerous opportunities for the key players, as pancreatic cancer is a highly challenging disease among all types of cancer, which has no specific treatment available for it, as of now. Also, growing incidence of cancer and technological advancements are supporting the growth of the global pancreatic cancer therapeutics market growth.

Cancer instigates uncountable growth of cells due to some abnormalities in the body. Some of the common symptoms of pancreatic cancer include weight loss, diarrhea, jaundice and abdominal pain. Cancer hampers the pancreas’ normal functioning, with smoking being the major risk factor for pancreatic cancer. Diagnosis of this type of cancer is done by patient history check and complete physical examination, followed by urine, stool and blood tests. Also, personal or family history of pancreatitis and BRCA2 mutation inclines a person to be affected by pancreatic cancer.

Request to Get the Sample Pages at:

In developing countries, improvement in patient-centered care is being encouraged, as governments are investing huge amount of funds. Increasing elderly population base, high prevalence of pancreatic cancer and increase in foreign investments may be observed, over the forecast period, in the developing nations such as Asia-Pacific and Middle East Asia.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=pancreatic-cancer-therapeutics-market

The investment in both segments of pancreatic cancers is significant. However, the growing prevalence and growing reach of novel techniques in the developing regions are the aspects likely to drive the growth of the exocrine category, throughout the forecast period.

Presently, the global pancreatic cancer therapeutics industry is merged in nature, with only a few top companies seizing the major share of the market. Some of the top companies operating in this market are Celgene Corporation; Eli Lilly and Company; Amgen, Inc.; F. Hoffmann-La Roche AG; PharmaCyte Biotech, Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Clovis Oncology; Pfizer, Inc.; and Merck & Co., Inc.

Several companies are concentrating on the introduction of technologically advanced products, in order to obtain a significant share in the fast-growing medical devices area. Also, collaborations, mergers and partnerships with well-established players are the key approaches followed by top players to increase their market share, during the forecast period.

Read More

Integrated CDSS Segment Expected to Realize Fastest Growth in the Global CDSS Market, During Forecast Period

The clinical decision support system market size is expected to cross $1.5 billion by 2022, growing at a CAGR of 21.5% between 2016-2022. The CDSS market is driven by five major factors, including growing demand for advanced healthcare information systems, growing investments by HIT players, growing need for remote patient monitoring services, and increasing support from government organizations.

Download report sample at@ https://www.psmarketresearch.com/market-analysis/clinical-decision-support-system-market/report-sample

The massive unexplored CDSS across the globe has created abundant opportunities for the major players to exploit the potential of the CDSS market. Although, there has been significant development in the developed economies of European Union (EU) and the U.S., the clinical decision support system market is still at its nascent form, especially in the developing countries of Asia, Latin America, and Africa. A high growth in numbers of end user including hospitals, and pharmacy has been witnessed in the developing countries of these regions, which provides immense growth opportunities for the CDSS market.

The Asia-Pacific market for CDSS is expected to grow at a CAGR of 23.2% between 2016-2022. The clinical decision support system market in Asia-Pacific is growing, due to growing geriatric population and upsurge in the occurrence rate of different chronic diseases. In addition, the improving healthcare infrastructure, and favorable government support, such as investments and grants has fueled the demand of HIT systems including CDSS in the region. China is expected to grow at a CAGR of 27% during the forecast period and reach $114.3 million by 2022, in the Asia-Pacific CDSS market.

Explore Report at@ https://www.psmarketresearch.com/market-analysis/clinical-decision-support-system-market

Some of the key companies operating in the CDSS market include Cerner Corporation, RELX Group PLC, Epic Systems Corporation, General Electric Company, McKesson Corporation, Zynx Health Incorporated, International Business Machine Corporation, Siemens AG, Allscripts Healthcare Solutions Inc., Meditech and Wolters Kluwer.

GLOBAL CDSS MARKET SEGMENTATION

By Product

• Integrated CDSS Solutions
• Standalone CDSS Solutions

By Application

• Drug Dosing Support
• Clinical Guidelines
• Clinical Reminders
• Drug-Drug Interactions
• Drug Allergy Alerts
• Others

By Model

• Knowledge-based CDSS Solutions
• Non-Knowledge-Based CDSS Solutions

By Mode of Delivery

• On-Premises
• Web-Based
• Cloud-Based

By Component

• Software
• Hardware
• Services

By Healthcare Provider Entity Capacity

• Less than 100 Beds
• 100–199 Beds
• 200–299 Beds
• 300–399 Beds
• 400–499 Beds
• More than 500 Beds

By Region

• North America
• U.S.
• Canada
• Rest of North America
• Western Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Central & Eastern Europe
• Russia
• Rest of Central & Eastern Europe
• Asia-Pacific
• China
• Japan
• India
• Australia
• Rest of Asia-Pacific
• Latin America
• Brazil
• Rest of Latin America
• Middle East and Africa

Source: P&S Intelligence

Read More

Pain Management Drugs Market Segmental Analysis by Therapeutics, Diagnostics, Patient, Drugs Policy and Regulatory Landscape

The growing geriatric population and increasing demand of innovative and advanced pain relaxing medications around the world are the predominant growth drivers for the global pain management drugs market. Additionally, the increasing number of hospitalization cases; unmet requirements for neuropathic pain management drugs; innovative and advanced applications of pain management therapies; increasing prevalence of various chronic diseases, such as cancer, and neurological problems; and increasing healthcare expenditure are also driving the growth of the global market. The growing numbers of mergers and acquisitions is a key trend observed in the market. Among the various therapeutic indications, the post-operative pain relief segment accounted for the largest share, and the low-back pain segment accounted for the second largest share in the global market.

Pain management drugs are mainly used to relieve discomfort associated with injury and surgeries. Moreover, pain management medications are used in the management of pain associated with neurological problems, migraine, cancer, orthopedic problems, low- back pain, rheumatoid arthritis, and fibromyalgia.

Request to Get the Sample Pages at: 

North America and Europe are the major markets, due to increasing prevalence of chronic diseases, and growing awareness about various types of chronic pain conditions in these regions. The U.S. followed by Canada, is the largest market for pain management drugs in North America. Whereas, the U.K., Germany and France are some of the major countries holding significant share in the European pain management drugs market.

The Asian market is growing with a significant rate, owing to huge pool of patients, and increasing healthcare spending in the region. In addition, the initiatives taken by various government associations to develop chronic pain rehabilitation centers, and increasing prevalence of various chronic diseases are also supporting the growth of the Asian pain management drugs market. The countries such as India, Japan and China, are the major markets in the region.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=pain-management-drugs-market

Apart from these regions, Latin America is another important market. This is due to increasing investments by drug manufacturing companies and growing demand of pain management medications in the region. Brazil holds the largest share in the Latin American pain management drugs market, due to the increasing support from government organizations for the development of chronic pain rehabilitation center in the country.

Some of the major players operating in the global pain management drugs market include Purdue Pharma L.P., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Forest Laboratories Inc., Endo International PLC, Johnson & Johnson, Pfizer Inc., Valeant Pharmaceuticals International Inc., GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd., and Baxter International Inc.

Pain Management Drugs Market Segmentation

By Category

•              Prescription-Based Drugs

•              Over-The-Counter (OTC) Drugs

By Therapeutic Indications

•              Post-Operative Pain

•              Low-Back Pain

•              Rheumatoid Arthritis Pain

•              Osteoarthritis Pain

•              Cancer Pain

•              Migraine

•              Neuropathic Pain

•              Fibromyalgia

•              Others

By Brands

•              Maxalt

•              Zomig

•              Qutenza

•              Lidoderm

•              Savella

•              Imitrex

•              Voltaren Gel

•              Celebrex

•              Cymbalta

•              Others

By Geography

•              North America

o              U.S.

o              Canada

•              Europe

o              Germany

o              France

o              U.K.

o              Spain

o              Italy

•              Asia

o              Japan

o              China

o              India

•              Latin America

o              Brazil

•              Rest of the World

Read More

Neuroendocrine Carcinoma Therapeutics Market Outlook, Growth Opportunities, Major Competitors and Porter Analysis

Global neuroendocrine carcinoma therapeutics market is witnessing significant growth due to large number of marketed drugs and Phase III drugs. Neuroendocrine carcinoma is a tumor that begins in neuroendocrine cells and can spread, or metastasize, to other parts of the body. It starts in the hormone producing cells of the body’s neuroendocrine system. Neuroendocrine tumors can begin in many organs including, lungs, brain and gastrointestinal tract. It is a very rare cancer with symptoms such as hyperglycemia, hypoglycemia, diarrhea, weight loss, pain, cough, lump formation, jaundice, unusual bleeding, headache and anxiety. The risk factors of developing neuroendocrine cancer includes, age, gender, family history, immune system suppression, arsenic exposure and sun exposure. The diagnosis can be done by normal physical examination followed by blood tests, urine tests, X- ray, CT scan, PET scan, MRI and biopsy.

The treatments available for neuroendocrine tumor include chemotherapy, surgery and radiation therapy. Chemotherapy comprises the drug’s use to destroy malignant cells by hindering the cells ability to divide and grow. Streptozocin (Zanosar) and 5-fluorouracil (Adrucil, 5-FU) are some of the drugs that are used to treat neuroendocrine tumors. Many pharmaceutical companies have been working continuously for the development of targeted therapy for the growth of neuroendocrine cancer market.

Request to Get the Sample Pages at: 

Sunitinib (Sutent) and Everolimus (Afinitor) are two major targeted drugs that are being used for treatment of neuroendocrine cancer. Genentech Inc., F. Hoffmann-La Roche Ltd., Callisto Pharmaceuticals Pvt. Ltd. and BioSynthema, Inc. are some major companies that are determined to develop therapeutics for various neuroendocrine cancers. Lutathera, Atiprimod and Avastin are pipeline candidates that are presently being studied for their therapeutic efficacy in the treatment of neuroendocrine cancer. Also, there are many other pipeline drugs in Phase III which are expected to enter the neuroendocrine carcinoma therapeutics market in the future.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=neuroendocrine-carcinoma-therapeutics-market

Geographically, neuroendocrine carcinoma therapeutics market has been segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). According to Cancer.Net, approximately 8,000 people are identified with neuroendocrine cancer every year in the U.S. Several key players functioning in neuroendocrine carcinoma therapeutics market are based in the U.S and therefore consider North America as their main market for product launch and research and development investments. Also, entrenched infrastructure and favorable reimbursement scenario are the major factors accountable for the strengthening of North America’s neuroendocrine carcinoma therapeutics market. Europe is the second largest market for neuroendocrine carcinoma therapeutics, followed by Asia. Increasing prevalence of neuroendocrine cancer in Asia Pacific along with the refining economic scenario is expected to play an important role in driving the market growth in the region.

Some of the key players operating in the global neuroendocrine carcinoma therapeutics market include Pfizer Ltd., Eli Lilly & Company, Novartis AG, F. Hoffmann-La Roche Ltd., Ispen SA, Amgen, Inc., Teva Pharmaceuticals, Ltd. and Bristol-Myers Squibb among others.

Read More